Research guide · Metabolic Support
Semaglutide — research protocol
GLP-1 receptor agonist studied for appetite regulation, weight management and metabolic control.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- GLP-1 receptor agonist
- The most studied weight-management peptide
- Lyophilized powder for maximum stability
- 99% HPLC verified purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Semaglutide is a GLP-1 receptor agonist available in injectable (once weekly) and oral tablet (once daily) forms, used for weight loss and diabetes. Doses start low and escalate every 4 weeks to allow the body to adjust.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Injectable (Wegovy weight-management) | 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg | Once per week | 4 weeks each, then ongoing | Subcutaneous injection |
| Injectable (Ozempic type 2 diabetes) | 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg | Once per week | 4 weeks each, then ongoing | Subcutaneous injection |
| Oral Tablet (Wegovy 25 mg pill for obesity) | 1.5 mg, 4 mg, 9 mg, 25 mg | Once per day | 4 weeks each, then ongoing | Oral tablet |
| Oral Tablet (Rybelsus type 2 diabetes) | 3 mg, 7 mg, 14 mg | Once per day | 4 weeks each, then ongoing | Oral tablet |
Cycle: Doses are increased every 4 weeks, with maintenance phases for ongoing weekly or daily administration depending on the route and condition.
Benefits and research observations: Tolerability is key in weeks 1-4. Appetite changes and side effects may appear in weeks 5-8, with significant effects and side effect stabilization by weeks 16-20.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Wilding JPH, et al. NEJM, 2021.
- 2.Jastreboff AM, et al. NEJM, 2022.